The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Molecular and clinical implications of CHD1 loss and SPOP mutations in advanced prostate cancer.
 
Pasquale Rescigno
No Relationships to Disclose
 
Gunther Boysen
Employment - Astellas Pharma
 
Daniel Nava Rodrigues
No Relationships to Disclose
 
George Seed
No Relationships to Disclose
 
David Dolling
No Relationships to Disclose
 
Ruth Riisnaes
No Relationships to Disclose
 
Mateus Crespo
No Relationships to Disclose
 
Diletta Bianchini
No Relationships to Disclose
 
Semini Sumanasuriya
No Relationships to Disclose
 
Ines Figueiredo
No Relationships to Disclose
 
Rossitza Christova
No Relationships to Disclose
 
Veronica Gil
No Relationships to Disclose
 
Jane Goodall
No Relationships to Disclose
 
Adam Sharp
No Relationships to Disclose
 
Mark A. Rubin
No Relationships to Disclose
 
Wei Yuan
No Relationships to Disclose
 
Christopher Barbieri
Patents, Royalties, Other Intellectual Property - A patent application has been filed regarding SPOP mutations in prostate cancer by Weill Cornell Medicine. I am a co-inventor.
 
Joaquin Mateo
Travel, Accommodations, Expenses - AstraZeneca; Sanofi
 
Suzanne Carreira
No Relationships to Disclose
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; Genentech/Roche; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Genentech/Roche; Merck Serono; Merck Sharp & Dohme; Pfizer; Sanofi
Research Funding - AstraZeneca (Inst); Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); PARP inhibitors and DNA repair defects (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex